Watch our webinar with Tissue Repair, featuring CEO & Co-Founder Tony Charara. A presentation followed by live Q&A with the audience.

Tissue Repair Limited (ASX: TRP) is a Phase 3 advanced biotechnology company developing second-generation wound healing agents. The Company’s core focus is entering Phase 3 clinical trials in chronic wounds for its lead drug candidate TR987®, with a secondary emphasis on commercialising TR Pro+®, a post-procedure topical gel to accelerate healing and improve skin quality following cosmetic and medical procedures, as well as other acute wound products in its pipeline. The Company’s longer-term strategy is to commercialise its proprietary Glucoprime® API to treat a variety of wounds and skin conditions.
Management tells one side of the story. Sharewise clients get independent research and Advisor access across ASX, US and global markets.